Interim report 2026
Filed with HKEX · Stock code 2696 · · 90 pages · English
Corporate Information Operation Highlights Management Discussion and Analysis Independent Review Report Interim Condensed Consolidated Statement of Profit or Loss 2 4 12 45 46 Interim Condensed Consolidated Statement of Comprehensive Income 47 Interim Condensed Consolidated Statement of Financial Position Interim Condensed Consolidated Statement of Changes in Equity Interim Condensed Consolidated
Shanghai Henlius Biotech, Inc. on 6ix
Earlier from Shanghai Henlius Biotech
- Voluntary announcement - collaboration and license agreement with amberstone for two T Cell Engager products
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
- Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
- FDA Approves Shanghai Henlius Biotech IND For Cetuximab Biosimilar
Later from Shanghai Henlius Biotech
- (1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees
- List of directors and their roles and functions
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Shanghai Henlius Biotech into a list and get an email when it puts out news.
Follow Shanghai Henlius Biotech